 |
22 Diseases |  |
2 Trials |
|
2 Trials |  |
107 News |  |
| «12 |
- ||||| lefitolimod (MGN1703) / OncXerna Therap, iPharma, Gilead
Trial initiation date, Immunomodulating, Metastases: IMPALA: Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment (clinicaltrials.gov) - May 19, 2014
P3, N=540, Not yet recruiting, Sponsor: Mologen AG
Initiation date: Jul 2014 --> Aug 2014
- | lefitolimod (MGN1703) / OncXerna Therap, iPharma, Gilead
Trial completion: A Phase I Study to Assess Cardiac and General Safety and Pharmacokinetics of 60 mg MGN1703 (clinicaltrials.gov) - May 15, 2014
P1, N=14, Completed, Sponsor: Mologen AG
Initiation date: Jul 2014 --> Aug 2014 Not yet recruiting --> Completed
- |||||||||| lefitolimod (MGN1703) / OncXerna Therap, iPharma, Gilead
New P3 trial, Immunomodulating, Metastases: IMPALA: Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment (clinicaltrials.gov) - Mar 2, 2014
P3, N=540, Not yet recruiting, Sponsor: Mologen AG
- | lefitolimod (MGN1703) / OncXerna Therap, iPharma, Gilead
New P1 trial: A Phase I Study to Assess Cardiac and General Safety and Pharmacokinetics of 60 mg MGN1703 (clinicaltrials.gov) - Nov 5, 2013
P1, N=14, Not yet recruiting, Sponsor: Mologen AG
- ||| lefitolimod (MGN1703) / OncXerna Therap, iPharma, Gilead
Enrollment change, Immunomodulating, Metastases: IMPACT: Efficacy Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma (clinicaltrials.gov) - Jun 24, 2012
P2, N=59, Active, not recruiting, Sponsor: Mologen AG
Not yet recruiting --> Completed N=129 --> 59
- ||| lefitolimod (MGN1703) / OncXerna Therap, iPharma, Gilead
Enrollment closed, Immunomodulating, Metastases: IMPACT: Efficacy Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma (clinicaltrials.gov) - Jun 24, 2012
P2, N=59, Active, not recruiting, Sponsor: Mologen AG
N=129 --> 59 Recruiting --> Active, not recruiting